The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results.
 
Michal Sternschuss
Honoraria - Medison
 
Brendan John Guercio
Honoraria - Medscape
Research Funding - Bristol-Myers Squibb (Inst); Genentech (Inst); Lilly (Inst); Oncocyte; Pfizer (I); Pfizer (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - EMD Serono; Gilead Sciences; Natera; Seattle Genetics/Astellas
 
Eugene J. Pietzak
Honoraria - UpToDate
Consulting or Advisory Role - Chugai Pharma; Janssen; Merck; QED Therapeutics; Urogen pharma
Research Funding - Janssen
 
Maria Ponomarev
No Relationships to Disclose
 
Ashley M. Regazzi
No Relationships to Disclose
 
Colleen Quinlan
No Relationships to Disclose
 
David H Aggen
Consulting or Advisory Role - Astellas Pharma; Boehringer Ingelheim; Bristol Myers Squibb Foundation; Seagen
Patents, Royalties, Other Intellectual Property - University of Illinois - Urbana Champaign
 
Alvin C. Goh
Consulting or Advisory Role - Medtronic
Travel, Accommodations, Expenses - Medtronic
 
Eugene K. Cha
No Relationships to Disclose
 
S. Machele Donat
No Relationships to Disclose
 
A. Ari Hakimi
Consulting or Advisory Role - Merck
 
Richard Matulewicz
No Relationships to Disclose
 
Samuel A Funt
Employment - ByHeart (I)
Stock and Other Ownership Interests - 76Bio (I); Allogene Therapeutics; Doximity; IconOVir Bio (I); Kite, a Gilead company; Kronos Bio; Neogene Therapeutics (I); Urogen pharma (I); Vida Ventures (I)
Consulting or Advisory Role - BioNtech; Immunai; Merck
Research Funding - AstraZeneca (Inst); Decibel Therapeutics (Inst); Genentech/Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Bristol-Myers Squibb
 
Dean F. Bajorin
Honoraria - Bristol-Myers Squibb/Medarex
Consulting or Advisory Role - Bristol Myers Squibb Foundation; Merck
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Seattle Genetics/Astellas (Inst)
 
Gopa Iyer
Consulting or Advisory Role - Bicycle Therapeutics; Flare Therapeutics; Janssen; Loxo/Lilly; Mirati Therapeutics
Speakers' Bureau - Gilead Sciences; Lynx Group
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Janssen (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Seagen (Inst)
 
Irina Ostrovnaya
No Relationships to Disclose
 
Hikmat A. Al-Ahmadie
Consulting or Advisory Role - AstraZeneca/MedImmune; Flare Therapeutics; Janssen Biotech; PAIGE.AI
 
Jonathan E. Rosenberg
Honoraria - Clinical Care Options; Medscape; MJH Life Sciences; NCCN/Pfizer; Peerview; Pfizer; Physicans' Education Resource; Research To Practice; UpToDate
Consulting or Advisory Role - Alligator Bioscience; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Century Therapeutics; Gilead Sciences; GlaxoSmithKline; Hengrui Pharmaceutical; Immunomedics; Imvax; Janssen Oncology; Lilly; Merck; Mirati Therapeutics; Pfizer/EMD Serono; QED Therapeutics; Roche/Genentech; Seagen; Tyra Biosciences
Research Funding - Acrivon Therapeutics; Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech/Roche (Inst); QED Therapeutics (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - Predictor of platinum sensitivity (Inst)
 
Jonathan Coleman
Travel, Accommodations, Expenses - Digital Angiography Reading Center (I)
(OPTIONAL) Uncompensated Relationships - AngioDynamics; Steba Biotech
 
Min Yuen Teo
Consulting or Advisory Role - Janssen Oncology
Research Funding - Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Pharmacyclics (Inst)